{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:43:17Z","timestamp":1760820197923},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/iae.0b013e3181c700a9","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T08:17:41Z","timestamp":1262679461000},"page":"85-92","source":"Crossref","is-referenced-by-count":13,"title":["INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY"],"prefix":"10.1097","volume":"30","author":[{"given":"\u00c2NGELA M.","family":"CARNEIRO","sequence":"first","affiliation":[]},{"given":"MANUEL S.","family":"FALC\u00c3O","sequence":"additional","affiliation":[]},{"given":"ELISETE M.","family":"BRAND\u00c3O","sequence":"additional","affiliation":[]},{"given":"FERNANDO M.","family":"FALC\u00c3O-REIS","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archopht.121.11.1621","article-title":"Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.","volume":"121","author":"Bressler","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ajo.2003.11.069","article-title":"The epidemiology of age-related macular degeneration.","volume":"137","author":"Klein","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States.","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2014verteporfin in photodynamic therapy report 2.","volume":"131","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R7-11-20210130","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials\u2014TAP report 2.","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration.","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R10-11-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study.","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajo.2007.09.031","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.","volume":"145","author":"Bashshur","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archopht.125.10.1357","article-title":"Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.","volume":"125","author":"Bashshur","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00417-007-0654-x","article-title":"Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.","volume":"246","author":"Ladewig","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/IAE.0b013e318042b53f","article-title":"Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.","volume":"27","author":"Goff","year":"2007","journal-title":"Retina"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/IAE.0b013e3180654240","article-title":"Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration.","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00417-003-0650-8","article-title":"Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.","volume":"241","author":"Wachtlin","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cell.2005.10.036","article-title":"VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.","volume":"124","author":"Grunewald","year":"2006","journal-title":"Cell"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/IAE.0b013e3180ca9ad9","article-title":"Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.","volume":"27","author":"Ladas","year":"2007","journal-title":"Retina"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/01.iae.0000300915.81866.b8","article-title":"Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the Medicare population.","volume":"27","author":"Zlateva","year":"2007","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201001000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:23:50Z","timestamp":1618277030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201001000-00011"}},"subtitle":["One-Year Results"],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181c700a9","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}